Vapotherm, Inc. (VAPO)
| Market Cap | 6.14M |
| Revenue (ttm) | 67.60M |
| Net Income (ttm) | -69.45M |
| Shares Out | 6.14M |
| EPS (ttm) | -14.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,171 |
| Open | 1.01 |
| Previous Close | 1.12 |
| Day's Range | 0.92 - 1.01 |
| 52-Week Range | 0.78 - 23.52 |
| Beta | -1.08 |
| Analysts | Sell |
| Price Target | 1.00 (0.0%) |
| Earnings Date | Nov 8, 2023 |
About VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also pr... [Read more]
Financial Performance
In 2022, Vapotherm's revenue was $66.80 million, a decrease of -41.04% compared to the previous year's $113.29 million. Losses were -$113.26 million, 89.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for VAPO stock is "Sell" and the 12-month stock price forecast is $1.0.
News
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX
EXETER, N.H. , Dec. 14, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determine...
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of V...
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
EXETER, N.H. , Dec. 11, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock E...
Vapotherm Educates over 8,000 Clinicians in Respiratory Care Month
EXETER, N.H. , Nov. 28, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high veloci...
Vapotherm Reports Third Quarter 2023 Financial Results
EXETER, N.H. , Nov. 8, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2023 financial results and related highlights.
Vapotherm To Report Third Quarter 2023 Financial Results
EXETER, N.H. , Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the...
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® pr...
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® pr...
Vapotherm Reports Second Quarter 2023 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2023 financial results. Second Quarter 2023 Summary and Highlights Net reven...
Vapotherm To Report Second Quarter 2023 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the second quarter of 2023 after the close of tr...
Vapotherm Reports First Quarter 2023 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total reven...
Vapotherm To Report First Quarter 2023 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it will release financial results for the first quarter of 2023 after the close of tra...
Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...
Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results
EXETER, New Hampshire--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary...
Vapotherm Announces Closing of $23 Million Private Placement
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.
Vapotherm Announces $23 Million Private Placement
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc.
Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...
Vapotherm Announces Amendment to Debt Agreement
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary V...
Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...
Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...
Vapotherm Reports Second Quarter 2022 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the se...
Vapotherm to Report Second Quarter 2022 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapo...
Vapotherm to Participate in the William Blair 42nd Annual Growth Stock Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vap...